- このスレッドは終了し、閲覧専用となっています。
- コメントの投稿、最新コメントの閲覧はこちらの最新スレッドをご利用ください。
掲示板のコメントはすべて投稿者の個人的な判断を表すものであり、
当社が投資の勧誘を目的としているものではありません。
-
-
212
今が一番仕込みどき! クリスマス🎄🎅プレゼント🎁 期待して下さい^ - ^ 第三キャンプ⛺️にて、ナス ロックオン監視強化
-
(゚Д゚)今がチャンスです、導出して欲しいですね。
-
【NN102 SPRINT-MS】
~Summer 2018
Results of other imaging metrics -
(゚Д゚)運を天に任せるのです。
-
What is advance imaging analysis?
-
【A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis-2/2】
Instead, focal intra-axonal mitochondrial pathology is the earliest ultrastructural sign of damage, and it precedes changes in axon morphology. Molecular imaging and pharmacological experiments show that macrophage-derived reactive oxygen and nitrogen species (ROS and RNS) can trigger mitochondrial pathology and initiate FAD. Indeed, neutralization of ROS and RNS rescues axons that have already entered the degenerative process. Finally, axonal changes consistent with FAD can be detected in acute human multiple sclerosis lesions. In summary, our data suggest that inflammatory axon damage might be spontaneously reversible and thus a potential target for therapy.
Source:nature medicine -
【A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis-1/2】
Abstract
In multiple sclerosis, a common inflammatory disease of the central nervous system, immune-mediated axon damage is responsible for permanent neurological deficits1,2. How axon damage is initiated is not known. Here we use in vivo imaging to identify a previously undescribed variant of axon damage in a mouse model of multiple sclerosis. This process, termed 'focal axonal degeneration' (FAD), is characterized by sequential stages, beginning with focal swellings and progressing to axon fragmentation. Notably, most swollen axons persist unchanged for several days, and some recover spontaneously. Early stages of FAD can be observed in axons with intact myelin sheaths. Thus, contrary to the classical view2,3,4,5,6, demyelination—a hallmark of multiple sclerosis—is not a prerequisite for axon damage.
Source:nature medicine -
-
【Key word】
Axonal loss -
The top-line results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in progressive MS will be presented by Dr. Robert Fox, Staff Neurologist at the Cleveland Clinic and the principal investigator of this clinical trial, as a late-breaking oral platform presentation, which begins at 8:30 a.m. on October 28, 2017 at the 7th Joint ECTRIMS* – ACTRIMS** Meeting in Paris, France.
Source:MediciNova, Inc. Website -
でも茄子はどんだけ懐疑的なんやと思うのは俺だけか?
-
191
28日の博士のセッションが影響すると思うので、この辺はあまりJASDAQには影響なさそう。
-
(゚Д゚)これはこれでいい結果が出ると思う。
-
Because I think The American stock market has no price limit.
-
アナウンスへの評価か???
日本はS高、さてNASは今日、この結果受けてどう評価する??? -
何故こっちは寄り天で日本(4875 MEDICINOVA, INC.)はS高だったのでしょうか?
-
184
Now It is a big chance to have a dream because MNOV is not yet evaluated.
-
いい結果を出してくれますように👀💕➰💰
-
Is it faint or feint?
読み込みエラーが発生しました
再読み込み
後場高コ 2017年11月4日 02:05
>>212
ホンマに信じて良えんですか、クリスマス🎅🎁🎄